Damon R. Race, MBA, CLP, CMT – CEO Mr. Race is the President and CEO of GeneVentiv Therapeutics. Mr. Race is responsible for advancing GeneVentiv Therapeutics’ business and product candidates. Mr. Race has over 28 years of commercial pharmaceutical, public and private investment experience. Mr. Race earned his B.S. in Biology from George Mason University and his MBA from Duke University’s Fuqua School of Business. Mr. Race holds the Certified Licensing Professional® designation from the Licensing Executive Society, is a Chartered Market Technician® Charterholder and holds the FINRA Series 65. Mr. Race serves in a number of board, advisory and volunteer roles.